Hizentra
human normal immunoglobulin (SCIg)
Table of contents
Overview
Hizentra is used in patients whose blood does not contain enough antibodies (proteins that help the body to fight infections and other diseases), also known as immunoglobulins. It is used to treat the following conditions:
- primary immunodeficiency syndromes (PID, when people are born with an inability to produce enough antibodies);
- low levels of antibodies in the blood in patients with chronic lymphocytic leukaemia (a cancer of a type of white blood cell) or myeloma (a cancer of another type of white blood cell) and who have frequent infections;
- low levels of antibodies in the blood in patients before or after allogeneic haematopoietic stem cell transplantation (a procedure where the patient's bone marrow is cleared of cells and replaced by stem cells from a donor);
- chronic inflammatory demyelinating polyneuropathy (CIDP). In this rare disease, the immune system (the body’s defence system) works abnormally and destroys the protective covering over the nerves.
Hizentra contains the active substance human normal immunoglobulin.
This EPAR was last updated on 16/09/2020
Authorisation details
Product details | |
---|---|
Name |
Hizentra
|
Agency product number |
EMEA/H/C/002127
|
Active substance |
human normal immunoglobulin (SCIg)
|
International non-proprietary name (INN) or common name |
human normal immunoglobulin (SCIg)
|
Therapeutic area (MeSH) |
Immunologic Deficiency Syndromes
|
Anatomical therapeutic chemical (ATC) code |
J06BA01
|
Publication details | |
---|---|
Marketing-authorisation holder |
CSL Behring GmbH
|
Revision |
20
|
Date of issue of marketing authorisation valid throughout the European Union |
14/04/2011
|
Contact address |
Product information
23/07/2020 Hizentra - EMEA/H/C/002127 - II/0111/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Immune sera and immunoglobulins
Therapeutic indication
Therapeutic indication
Replacement therapy in adults and children in primary immunodeficiency syndromes such as:
- congenital agammaglobulinaemia and hypogammaglobulinaemia;
- common variable immunodeficiency;
- severe combined immunodeficiency;
- immunoglobulin-G-subclass deficiencies with recurrent infections;
- replacement therapy in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.